127 related articles for article (PubMed ID: 38053287)
1. Gene of the month: DDIT3.
Diaz-Perez JA; Kerr DA
J Clin Pathol; 2024 Mar; 77(4):211-216. PubMed ID: 38053287
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
[TBL] [Abstract][Full Text] [Related]
3. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
[TBL] [Abstract][Full Text] [Related]
4. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
[TBL] [Abstract][Full Text] [Related]
5. Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma.
Mantilla JG; Ricciotti RW; Chen EY; Liu YJ; Hoch BL
Mod Pathol; 2019 Apr; 32(4):585-592. PubMed ID: 30420727
[TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.
Baranov E; Black MA; Fletcher CDM; Charville GW; Hornick JL
Mod Pathol; 2021 Jul; 34(7):1367-1372. PubMed ID: 33731886
[TBL] [Abstract][Full Text] [Related]
7. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.
Bode-Lesniewska B; Frigerio S; Exner U; Abdou MT; Moch H; Zimmermann DR
Genes Chromosomes Cancer; 2007 Nov; 46(11):961-71. PubMed ID: 17647282
[TBL] [Abstract][Full Text] [Related]
8. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
[TBL] [Abstract][Full Text] [Related]
9. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
[TBL] [Abstract][Full Text] [Related]
10. DDIT3-amplified or low-polysomic pleomorphic sarcomas without MDM2 amplification: Clinicopathological review and immunohistochemical profile of nine cases.
Mori T; Iwasaki T; Sonoda H; Kawaguchi K; Tomonaga T; Furukawa H; Sato C; Shiraishi S; Taguchi K; Tamiya S; Yoneda R; Oshiro Y; Matsunobu T; Abe C; Kuboyama Y; Ueki N; Kohashi K; Yamamoto H; Nakashima Y; Oda Y
Hum Pathol; 2024 Mar; 145():56-62. PubMed ID: 38401716
[TBL] [Abstract][Full Text] [Related]
11. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
[TBL] [Abstract][Full Text] [Related]
12. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
13. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
[TBL] [Abstract][Full Text] [Related]
14. A cryptic EWSR1::DDIT3 fusion in myxoid liposarcoma: Potential pitfalls with FISH and cytogenetics.
Ibstedt S; de Mattos CBR; Köster J; Mertens F
Genes Chromosomes Cancer; 2023 Mar; 62(3):167-170. PubMed ID: 36379683
[TBL] [Abstract][Full Text] [Related]
15. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract][Full Text] [Related]
16. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.
Pérez-Mancera PA; Bermejo-Rodríguez C; Sánchez-Martín M; Abollo-Jiménez F; Pintado B; Sánchez-García I
PLoS One; 2008 Jul; 3(7):e2569. PubMed ID: 18596980
[TBL] [Abstract][Full Text] [Related]
17. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
[TBL] [Abstract][Full Text] [Related]
18. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
[TBL] [Abstract][Full Text] [Related]
19. DNA damage-inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression.
Vargas AC; Chan NL; Wong DD; Zaborowski M; Fuchs TL; Ahadi M; Clarkson A; Sioson L; Sheen A; Maclean F; Bonar F; Cheah A; Jones M; Chou A; Gill AJ
Histopathology; 2021 Jul; 79(1):106-116. PubMed ID: 33465826
[TBL] [Abstract][Full Text] [Related]
20. A Patient with Myxoid/Round Cell Liposarcoma (MRCL) Involving the Well-known Translocation t(12;22): A Case Report with the Cytogenomic Landscape of this Rearrangement.
Tirado CA; Su W; Chia V; Zaki M; Tang R; Eastwood K; Guardiola MT; Rao A
J Assoc Genet Technol; 2022; 48(2):68-75. PubMed ID: 35660675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
